Shots:

• Janssen partnered with BARDA to accelerate the development of its investigational coronavirus vaccine program. Both will partake to the research and development cost and mobilize resources to advance Janssen’s COVID-19 vaccine program
• BARDA to provide a fund to expedite the development of vaccine into P-I study with an option for additional funding to advance a promising candidate while Janssen will upscale the production capacities to meet the public health needs
• COVID-19 vaccine program will leverage Janssen’s AdVac and PER.C6 technologies- providing the ability to upscale production of the optimal vaccine therapy. The company utilizes its same technology in its Ebola vaccine- currently being administered in the Democratic Republic of Congo and Rwanda

Click here ­to­ read full press release/ article 

Ref: J&J | Image: Janssen